Madrigal Pharmaceuticals (MDGL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Key Insights
Critical company metrics and information
Share Price
$318.48Market Cap
$6.95 BillionTotal Outstanding Shares
21.81 Million SharesTotal Employees
376Dividend
No dividendIPO Date
February 6, 2007SIC Description
Pharmaceutical PreparationsHomepage
http://www.madrigalpharma.com
Historical Stock Splits
If you bought 1 share of MDGL before July 25, 2016, you'd have 0.03 shares today.
| Execution Date | Split Amount |
|---|---|
| July 25, 2016 | 1-for-35 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-202.39 Million |
| Net Cash Flow From Financing Activities | $7.46 Million |
| Net Cash Flow, Continuing | $-261.91 Million |
| Net Cash Flow From Financing Activities, Continuing | $7.46 Million |
| Net Cash Flow | $-261.91 Million |
| Net Cash Flow From Investing Activities | $-202.39 Million |
| Net Cash Flow From Operating Activities, Continuing | $-66.98 Million |
| Net Cash Flow From Operating Activities | $-66.98 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Basic Average Shares | $21.75 Million |
| Diluted Earnings Per Share | $4.92 |
| Diluted Average Shares | $21.75 Million |
| Costs And Expenses | $178.48 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-106.96 Million |
| Interest Expense, Operating | $3.68 Million |
| Revenues | $62.17 Million |
| Basic Earnings Per Share | $4.92 |
| Selling, General, and Administrative Expenses | $107.58 Million |
| Net Income/Loss Attributable To Parent | $-106.96 Million |
| Income/Loss From Continuing Operations After Tax | $-106.96 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss | $-106.96 Million |
| Other Operating Expenses | $70.89 Million |
| Operating Expenses | $178.48 Million |
| Benefits Costs and Expenses | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $62.17 Million |
| Operating Income/Loss | $-116.30 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Inventory | $8.71 Million |
| Other Current Liabilities | $102.20 Million |
| Noncurrent Assets | $9.60 Million |
| Liabilities | $296.11 Million |
| Current Liabilities | $177.85 Million |
| Equity | $777.15 Million |
| Wages | $29.68 Million |
| Accounts Payable | $45.97 Million |
| Other Non-current Assets | $7.33 Million |
| Fixed Assets | $2.27 Million |
| Liabilities And Equity | $1.07 Billion |
| Other Current Assets | $51.32 Million |
| Current Assets | $1.06 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Non-current Liabilities | $1.18 Million |
| Long-term Debt | $117.09 Million |
| Cash | $1.00 Billion |
| Equity Attributable To Parent | $777.15 Million |
| Noncurrent Liabilities | $118.26 Million |
| Assets | $1.07 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.